Minireviews
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Pharmacol. Dec 9, 2013; 2(4): 107-114
Published online Dec 9, 2013. doi: 10.5497/wjp.v2.i4.107
Aryl hydrocarbon receptor as a new therapeutic target for cancer and immune disorders
Libia Vega, Guillermo Elizondo
Libia Vega, Departamento de Toxicología, CINVESTAV-IPN, Zacatenco, CP 07360, México city, México
Guillermo Elizondo, Departamento de Biología Celular, CINVESTAV-IPN, Zacatenco, CP 07360, México city, México
Author contributions: All authors contributed to this work.
Supported by SEP-CONACYT Grant, No. 153377
Correspondence to: Guillermo Elizondo, PhD, Departamento de Biología Celular, CINVESTAV-IPN, Zacatenco, Av. IPN 2508, CP 07360, México city, México. gazuela@cinvestav.mx
Telephone: +52-55-57473800 Fax: +52-55-57473393
Received: June 28, 2013
Revised: August 9, 2013
Accepted: August 16, 2013
Published online: December 9, 2013
Processing time: 173 Days and 17.7 Hours
Core Tip

Core tip: The goal of the present review was to discuss the role of the aryl hydrocarbon receptor (AhR) in cell proliferation and immune responses, and to highlight the potential for AhR to serve as a therapeutic target for cancer and immune diseases.